health
February 6, 2026
Hims & Hers shares tick lower after Novo's legal threat
Hims & Hers stock ticked lower Friday after Novo Nordisk said its newly announced Wegovy pill copy was illegal and that it would take legal action.
TL;DR
- Hims & Hers plans to launch a cheaper version of Novo Nordisk's weight loss pill, semaglutide, for $49-$99.
- Novo Nordisk has threatened legal action, calling Hims' plan "illegal" and a patient safety risk.
- Hims is utilizing a loophole for compounded drugs, although semaglutide has patent protection until 2032.
- Novo Nordisk states there are no supply shortages for the pill version of its drug.
- Hims' stock has been volatile, with analysts suggesting it could copy other weight loss drugs.
Continue reading the original article